anthrax vaccine, adsorbed
Trade name: Biothrax
Vaccineapproved
Approved
Jul 1, 1970
Anthrax vaccine adsorbed, sold under the brand name Biothrax among others, is a vaccine intended to provide acquired immunity against Bacillus anthracis. — Wikipedia
Clinical trial activity
18 trials · 21 clinical orgs · 1 marketing orgs
Phase 1
7
Phase 2
8
Phase 3
2
Phase 4
3
Earliest trial started May 1, 2002 (NCT00119067)
Timeline
1970s
- Jul 1, 1970
Earliest FDA Approval
1990s
- Nov 12, 1998
Emergent BioSolutions — First NDA Organization
- Nov 12, 1998
Emergent BioSolutions — NDA Secondary Org
- Nov 12, 1998
Emergent BioSolutions — NDA Organization
2010s
- Jan 1, 2011
Emergent BioSolutions — Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Biological vaccine - induces immune response
- Bacillus anthracisImmunity, active
Bacillus anthracis immunity, active
- Anthrax lethal factorImmunity, active
lef immunity, active
Approval history
- approvedJul 1, 1970
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAnthrax vaccine adsorbed ↗
- NCATS873OI62848 ↗
- ChEMBLCHEMBL2108573 ↗
Also known as
- anthrax antigen
- anthrax vaccine
- anthrax vaccine
- anthrax vaccine absorbed
- anthrax vaccine adsorbed
- anthrax vaccine adsorbed
- anthrax vaccine, adsorbed
- av7909
- av7909
- ava
- bacillus anthracis inactivated antigen
- bacillus anthracis strain v770-np1-r antigen
- bacillus anthracis strain v770-np1-r antigens
- bacillus anthracis strain v770-np1-r filtrate antigen
- bacillus anthracis strain v770-np1-r filtrate (attenuated) antigen
- biothrax
- protective antigen, anthrax vaccine adsorbed
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05997264 | Phase 2 | Dec 5, 2023 | Department of Health and Human Services, ICON, Rho, Inc. |
| NCT04660201 | Phase 1 | Jan 11, 2021 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT04148118 | Phase 1 | Dec 31, 2019 | BlueWillow Biologics, Porton Biopharma Ltd. |
| NCT04067011 | Phase 2 | Aug 12, 2019 | Department of Health and Human Services, Emergent BioSolutions |
| NCT03877926 | Phase 3 | Mar 11, 2019 | Department of Health and Human Services, Emergent BioSolutions |
| NCT03518125 | Phase 2 | May 9, 2018 | Clinical Research Associates, Inc., Coastal Carolina Research, Department of Health and Human Services, JBR Clinical Research, Johnson County Clin-Trials, Rho, Inc. |
| NCT03352466 | Phase 1 | Feb 3, 2018 | Altimmune, Inc., ICON |
| NCT02339155 | Phase 4 | Feb 1, 2015 | GlaxoSmithKline |
| NCT01770743 | Phase 2 | Jan 1, 2013 | Emergent BioSolutions, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01753115 | Phase 2 | Dec 1, 2012 | Department of Health and Human Services, Emergent BioSolutions |
| NCT01641991 | Phase 4 | Jul 1, 2012 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01491607 | Phase 3 | Nov 1, 2011 | Department of Health and Human Services, Emergent BioSolutions |
| NCT01263691 | Phase 1 | Dec 1, 2010 | Department of Health and Human Services, Emergent BioSolutions, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00133484 | Phase 2 | Aug 19, 2005 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00114621 | Phase 1 | Sep 8, 2004 | National Institutes of Health (NIH) |
| NCT00063843 | Phase 1 | Jul 1, 2003 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00057525 | Phase 1 | Apr 1, 2003 | DynPort Vaccine Company LLC, United States Army |
| NCT00119067 | Phase 4 | May 1, 2002 | Baylor University, Centers for Disease Control and Prevention (CDC), Emory University, Mayo Clinic, United States Army, University of Alabama, Birmingham |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (21)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Health and Human Services | Government | 7 | 2 | 3 | 2010 |
| Emergent BioSolutions | For profit | 6 | 6 | 3 | 2010 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 6 | 4 | 3 | 2003 |
| ICON | For profit | 2 | 0 | 2 | 2018 |
| Rho, Inc. | For profit | 2 | 0 | 1 | 2018 |
| United States Army | Government | 2 | 0 | 2 | 2002 |
| Altimmune, Inc. | For profit | 1 | 1 | 1 | 2018 |
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2002 |
| BlueWillow Biologics | For profit | 1 | 1 | 1 | 2019 |
| Centers for Disease Control and Prevention (CDC) | Government | 1 | 1 | 1 | 2002 |
| Clinical Research Associates, Inc. | For profit | 1 | 0 | 1 | 2018 |
| Coastal Carolina Research | For profit | 1 | 0 | 1 | 2018 |
| DynPort Vaccine Company LLC | For profit | 1 | 1 | 1 | 2003 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2002 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2015 |
| JBR Clinical Research | For profit | 1 | 0 | 1 | 2018 |
| Johnson County Clin-Trials | For profit | 1 | 0 | 1 | 2018 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2002 |
| National Institutes of Health (NIH) | Government | 1 | 1 | 1 | 2004 |
| Porton Biopharma Ltd. | For profit | 1 | 0 | 1 | 2019 |
21 organizations
Page 1 / 2
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Emergent BioSolutions | For profit | NDA2 | Nov 12, 1998 |
| Emergent BioSolutions | For profit | NDA | Nov 12, 1998 |